Fresenius' dialysis sales up 15%
This article was originally published in Clinica
German company Fresenius' dialysis sales rose 15% to DM 692 million ($455 million) in the first half of 1996. Fresenius says it expects its sales and profits to continue growing during 1996. The company intends to invest heavily in Asia and Latin America.
You may also be interested in...
AMAG outlines plans for retrospective real-world evidence studies, and possibly a new placebo-controlled trial with a primary endpoint of preterm birth <32 weeks, in a filing opposing the Center for Drug Evaluation and Research’s proposal to withdraw the drug.
The leading Korean pharma firm’s oral, third-generation EGFR-TKI is approved in the country, providing a new option for patients with advanced NSCLC and increasing hopes for global approvals given an ongoing global Phase III combination trial led by partner J&J.
DePuy Synthes expects its Velys robotic-assisted system to be cost-effective, easy-to-use and to be well-suited for use in ambulatory surgery centers.